Phase Ii Study Assessing Tolerability, Efficacy, And Biomarkers For Durvalumab (D) +/- Tremelimumab (T) And Gemcitabine/Cisplatin (Gemcis) In Chemo-Naive Advanced Biliary Tract Cancer (Abtc).

Do-Youn Oh,Kyung-Hun Lee,Dae-Won Lee,Tae Yong Kim,Ju-Hee Bang,Ah-Rong Nam,Young Lee,Qu Zhang,Marlon Rebelatto,Weimin Li,Jin Won Kim

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 68|浏览4

暂无评分

摘要

4520Background: In aBTC, GemCis is the standard of care as 1st-line treatment. Immunotherapies have shown early promising efficacy in some BTC patients (pts). We assessed D (anti-PD-L1) ± T (anti-C...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要